Literature DB >> 18413735

Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.

Longgui G Wang1, Edward M Johnson, Yayoi Kinoshita, James S Babb, Michael T Buckley, Leonard F Liebes, Jonathan Melamed, Xiao-Mei Liu, Ralf Kurek, Liliana Ossowski, Anna C Ferrari.   

Abstract

Increased androgen receptor (AR) expression and activity are pivotal for androgen-independent (AI) prostate cancer (PC) progression and resistance to androgen-deprivation therapy. We show that a novel transcriptional repressor complex that binds a specific sequence (repressor element) in the AR gene 5'-untranslated region contains Pur alpha and hnRNP-K. Pur alpha expression, its nuclear localization, and its AR promoter association, as determined by chromatin immunoprecipitation analysis, were found to be significantly diminished in AI-LNCaP cells and in hormone-refractory human PCs. Transfection of AI cells with a plasmid that restored Pur alpha expression reduced AR at the transcription and protein levels. Pur alpha knockdown in androgen-dependent cells yielded higher AR and reduced p21, a gene previously shown to be under negative control of AR. These changes were linked to increased proliferation in androgen-depleted conditions. Treatment of AI cells with histone deacetylase and DNA methylation inhibitors restored Pur alpha protein and binding to the AR repressor element. This correlated with decreased AR mRNA and protein levels and inhibition of cell growth. Pur alpha is therefore a key repressor of AR transcription and its loss from the transcriptional repressor complex is a determinant of AR overexpression and AI progression of PC. The success in restoring Pur alpha and the repressor complex function by pharmacologic intervention opens a promising new therapeutic approach for advanced PC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413735     DOI: 10.1158/0008-5472.CAN-07-6017

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.

Authors:  Ankur Sharma; Wen-Shuz Yeow; Adam Ertel; Ilsa Coleman; Nigel Clegg; Chellappagounder Thangavel; Colm Morrissey; Xiaotun Zhang; Clay E S Comstock; Agnieszka K Witkiewicz; Leonard Gomella; Erik S Knudsen; Peter S Nelson; Karen E Knudsen
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

3.  Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.

Authors:  Karen E Knudsen; William Kevin Kelly
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

Review 4.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 5.  Multiple roles for Puralpha in cellular and viral regulation.

Authors:  Martyn K White; Edward M Johnson; Kamel Khalili
Journal:  Cell Cycle       Date:  2009-02-10       Impact factor: 4.534

6.  Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer.

Authors:  Hua Zhou; Krystyna Mazan-Mamczarz; Jennifer L Martindale; Andrew Barker; Zhenqiu Liu; Myriam Gorospe; Peter J Leedman; Ronald B Gartenhaus; Anne W Hamburger; Yuexing Zhang
Journal:  Nucleic Acids Res       Date:  2010-02-16       Impact factor: 16.971

7.  Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.

Authors:  Changmeng Cai; David C Portnoy; Hongyun Wang; Xinnong Jiang; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

8.  LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion.

Authors:  Yirong Li; Longgui Wang; Miao Zhang; Jonathan Melamed; Xiaomei Liu; Robert Reiter; Jianjun Wei; Yi Peng; Xuanyi Zou; Angel Pellicer; Michael J Garabedian; Anna Ferrari; Peng Lee
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 9.  Stromal androgen receptor in prostate development and cancer.

Authors:  Mandeep Singh; Ruchi Jha; Jonathan Melamed; Ellen Shapiro; Simon W Hayward; Peng Lee
Journal:  Am J Pathol       Date:  2014-08-01       Impact factor: 4.307

10.  Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.

Authors:  P Barboro; E Repaci; A Rubagotti; S Salvi; S Boccardo; B Spina; M Truini; C Introini; P Puppo; N Ferrari; G Carmignani; F Boccardo; C Balbi
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.